2018 Second Quarter and R&D update
We announced our second quarter 2018 results on Wednesday 25 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our performance and financial outlook, and Hal Barron, Chief Scientific Officer and President, R&D, presented our R&D update.
- Q2 2018 results and R&D update announcement PDF - 1.0MB
- Q2 2018 slides - Emma Walmsley PDF - 495.7KB
- Q2 2018 slides - Simon Dingemans PDF - 131.7KB
- R&D update slides - Hal Barron PDF - 1.9MB
- Q2 2018 results transcript - Part 1 PDF - 188.4KB
- Q2 2018 results transcript - Part 2 PDF - 242.3KB
- Q2 2018 results infographic PDF - 556.7KB
- Q2 2018 US dollar translation PDF - 131.6KB
- Q2 2018 pre announcement aide memoire PDF - 742.2KB
2014 Fourth Quarter
Sir Andrew Witty, CEO, and Simon Dingemans, CFO, discuss our full year 2014 results.
2014 Third Quarter
Sir Andrew Witty, CEO, and Simon Dingemans, CFO, discuss our third quarter 2014 results.
- Q3 2014 results announcement PDF - 698.0KB
- Q3 2014 analyst webcast transcript PDF - 218.1KB
- Q3 2014 launch metrics and pipeline progress PDF - 150.2KB
- Q3 2014 restated finanical Information XLSX - 51.2KB
- Q3 2014 actual growth schedules PDF - 163.4KB
- Q3 2014 US dollar translation PDF - 143.8KB
- Q3 2014 pre announcement aide memoire PDF - 980.8KB
2014 Second Quarter
Sir Andrew Witty, CEO, and Simon Dingemans, CFO, discuss our second quarter 2014 results.
2014 First Quarter
Simon Dingemans, CFO, discusses our first quarter results 2014.
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III